Author

E. S. Yang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 11 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 9 Organism:human· 7 Assay:proteomics· 7 Research Focus:drug response / drug discovery· 6 Organism:mouse· 5 Research Focus:cell type annotation· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

L. Wang· 11 shared A. Pegu· 9 shared W. Shi· 9 shared J. R. Mascola· 8 shared K. Leung· 8 shared Y. Zhang· 8 shared C. A. Talana· 6 shared P. D. Kwong· 6 shared

Activity by Year

2019-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersImmunology

L. Wang

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

bioRxiv · Jul 29, 2022 · PreprintImmunology

Broadly neutralizing antibodies target the coronavirus fusion peptide

C. Dacon, C. Tucker, L. Peng, C.-C. D. Lee, T.-H. Lin, M. Yuan, Y. Cong, L. Wang, L. Purser, J. K. Williams, C.-W. Pyo, I. Kosik, Z. Hu, M. Zhao, D. Mohan, , J. Tan

The paper identifies six monoclonal antibodies that broadly neutralize coronaviruses by targeting the conserved fusion peptide.

bioRxiv · Apr 11, 2022Immunology

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

N. S. Lima, M. Musayev, T. S. Johnston, D. A. Wagner, A. R. Henry, L. Wang, E. S. Yang, Y. Zhang, K. Birungi, W. P. Black, S. O'Dell, S. D. Schmidt, D. Moon, C. G. Lorang, B. Zhao, , P. D. Kwong

The paper examines antibody responses to SARS-CoV-2 variants, finding convergent epitope specificities, V gene usage, and public B cell clones across different variants.

bioRxiv · Mar 28, 2022Immunology

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

W. Shi, L. Wang, T. Zhou, M. Sastry, E. S. Yang, Y. Zhang, M. Chen, X. Chen, M. Choe, A. Creanga, K. Leung, A. S. Olia, A. Pegu, R. Rawi, C.-H. Shen, , P. D. Kwong

This paper identifies an antibody, WS6, from a mouse immunized with SARS-CoV-2 spike mRNA, which neutralizes diverse beta-coronaviruses by targeting a conserved helical epitope on the S2 subunit.

bioRxiv · Jan 25, 2022Immunology

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D. R. Harris, A. S. Olia, C. A. Talana, E. S. Yang, M. Chen, M. Choe, W. Shi, I.-T. Teng, A. Creanga, C. Jenkins, , P. D. Kwong

The paper identifies potent monoclonal antibodies that neutralize the B.1.1.529 SARS-CoV-2 variant and reveals structural mechanisms enabling their effectiveness.

bioRxiv · Dec 27, 2021Immunology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

A. Pegu, S. E. O'Connell, S. D. Schmidt, S. O'Dell, C. A. Talana, L. Lai, J. Albert, E. Anderson, H. Bennett, K. Corbett, B. Flach, L. Jackson, B. Leav, J. E. Ledgerwood, C. J. Luke, , N. A. Doria-Rose

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

bioRxiv · May 13, 2021 · PreprintImmunology

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

H. Cho, K. K. Gonzales-Wartz, D. Huang, M. Yuan, M. Peterson, J. Liang, N. Beutler, J. L. Torres, Y. Cong, E. Postnikova, S. Bangaru, C. A. Talana, W. Shi, E. S. Yang, Y. Zhang, , J. Tan

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

bioRxiv · Apr 1, 2021 · PreprintImmunology

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

L. Wang, T. Zhou, Y. Zhang, E. S. Yang, C. A. Schramm, W. Shi, A. Pegu, O. K. Oloninyi, A. Ransier, S. Darko, S. R. Narpala, C. Hatcher, D. R. Martinez, Y. Tsybovsky, E. Phung, , Mascol

The paper identifies ultrapotent antibodies from convalescent donors that neutralize SARS-CoV-2 variants and reduce escape mutant generation.

bioRxiv · Feb 25, 2021Immunology

A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone

B. Zhang, C. W. Chao, Y. Tsybovsky, O. M. Abiona, G. B. Hutchinson, J. I. Moliva, A. S. Olia, A. Pegu, E. Phung, G. Stewart-Jones, R. Verardi, L. Wang, S. Wang, A. Werner, E. S. Yang, , P. D. Kwong

This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.

bioRxiv · Jun 11, 2020Immunology

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, , Wang

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

bioRxiv · Jun 11, 2020Immunology

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression

D. S. Chandrashekar, B. V. S. K. Chakravarthi, A. D. Robinson, J. C. Anderson, S. Agarwal, S. A. Hodigere Balasubramanya, M.-L. Eich, A. K. Bajpai, S. Davuluri, M. S. Guru, A. S. Guru, G. Naik, D. L. Della Manna, K. K. Acharya, S. Carskadon, , S. Varambally

This study identifies PAK4 amplification and overexpression in bladder cancer and shows PAK4 inhibition reduces tumor growth, with potential for combination therapy.

bioRxiv · Aug 20, 2019Cancer Biology